RxDoctor Payments Data

Emily Warrick

Physician Assistant · Axton, VANPI 1114559804

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 731 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 59 manufacturers, the largest accounting for just 15.3% — the pattern of someone who eats at a lot of different presentations. Among physician assistant clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$11,259in general payments, 2019–2025

Across 731 payments — averaging $15.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • Lilly USA, LLC$852
  • Otsuka America Pharmaceutical, Inc.$817
  • Pfizer$483
  • Lundbeck LLC$479
  • plus $6K from 53 others

What the payments were for

  • Food & beverage$11,259100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)120$1,721
Novo Nordisk86$1,240
Lilly USA, LLC58$852
Otsuka America Pharmaceutical, Inc.54$817
Pfizer40$483
Lundbeck LLC31$479
AstraZeneca24$463
Amgen31$438
GSK24$412
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC19$338
Merck18$271
Bayer16$267
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)16$240
Boehringer Ingelheim14$218
Mylan Specialty L.p.10$202
Takeda Pharmaceuticals U.S.A., Inc.10$184
Johnson & Johnson11$182
Astellas Pharma US Inc11$182
Currax Pharmaceuticals LLC11$175
Biohaven Pharmaceutical Holding Company Ltd.12$150
Dexcom, Inc.8$146
Vanda Pharmaceuticals Inc.6$139
Phathom Pharmaceuticals, Inc.7$135
Ardelyx, Inc.7$132
Ironwood Pharmaceuticals, Inc8$119
Nestle Healthcare Nutrition Inc.7$116
Aimmune Therapeutics, Inc.6$116
Alkermes, Inc.5$98
Novartis5$80
Biogen5$78
Idorsia Pharmaceuticals US Inc4$61
Sanofi-aventis U.S. LLC4$54
Eisai Inc.4$50
Amarin Pharma, Inc.3$50
Xeris Pharmaceuticals, Inc.3$50
Seqirus USA Inc3$45
Corium, LLC3$44
Axsome Therapeutics, Inc.2$33
ANI Pharmaceuticals, Inc.1$31
Phadia US Inc.2$30
E.r. Squibb & Sons, L.L.C.2$29
Medtronic2$28
Axonics, Inc.2$28
Biohaven Pharmaceuticals, Inc.1$27
Teva Pharmaceuticals USA, Inc.1$20
Lexicon Pharmaceuticals, Inc.1$17
Insulet Corporation1$17
Verona Pharma, Inc.1$16
Kowa Pharmaceuticals America, Inc.1$16
Organon1$16
Abbott1$16
Recordati_rare_diseases_inc.1$15
Impel Pharmaceuticals Inc.1$15
Esperion Therapeutics, Inc.1$15
Kaleo, Inc.1$14
Sanofi Pasteur Inc.1$14
Exact Sciences1$14
Vifor Pharma, Inc.1$12
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)1$11

How this compares

$11,259 in reported general payments places this provider in the 95th percentile of 3,376 physician assistant providers in Virginia.

See all physician assistant providers in Virginia

Medicare billing

Part B allowed, 2024
$29,608
Medicare patients
140
Services billed
1,203

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin14$43,459
OzempicSemaglutide30$41,492
JardianceEmpagliflozin45$32,950
TrulicityDulaglutide22$26,909
JanuviaSitagliptin Phosphate28$14,920
XareltoRivaroxaban15$11,613
MovantikNaloxegol Oxalate12$5,408
Breo ElliptaFluticasone/Vilanterol12$4,989
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$3,169
Albuterol Sulfate HfaAlbuterol Sulfate83$1,539
Levothyroxine Sodium108$1,425
Buspirone Hcl34$1,402
Omeprazole116$1,050
Atorvastatin Calcium103$902
Duloxetine Hcl32$896

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$338$43,45914 claims
Novo NordiskOzempic$1,240$41,49230 claims
Boehringer IngelheimJardiance$218$32,95045 claims
Lilly USA, LLCTrulicity$852$26,90922 claims
MerckJanuvia$271$14,92028 claims
Johnson & JohnsonXarelto$182$11,61315 claims
GSKBreo Ellipta$412$4,98912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,376 physician assistant providers in Virginia.

Other physician assistant in Axton

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →